Currently, there are 96.79M common shares owned by the public and among those 78.91M shares have been available to trade.
Insiders at the company have transacted a total of 49 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 417,638 shares. Insider sales of the common stock occurred on 27 occasions, with total insider shares sold totaling 44,064 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 41.55% and 347.12% over the past three months. ARQT shares are trading 187.93% year to date (YTD), with the 12-month market performance down to -45.74% lower. It has a 12-month low price of $1.76 and touched a high of $17.57 over the same period. ARQT has an average intraday trading volume of 5.60 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 61.70%, 126.08%, and 44.01% respectively.
Institutional ownership of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) shares accounts for 96.25% of the company’s 96.79M shares outstanding.
It has a market capitalization of $900.15M and a beta (3y monthly) value of 1.02. The earnings-per-share (ttm) stands at -$5.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.39% over the week and 13.21% over the month.
Analysts forecast that Arcutis Biotherapeutics Inc (ARQT) will achieve an EPS of -$0.78 for the current quarter, -$0.8 for the next quarter and -$2.59 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.96 while analysts give the company a high EPS estimate of -$0.48. Comparatively, EPS for the current quarter was -$1.18 a year ago. Earnings per share for the fiscal year are expected to increase by 30.77%, and 33.96% over the next financial year. EPS should grow at an annualized rate of 9.80% over the next five years, compared to -110.36% over the past 5-year period.
Looking at the support for the ARQT, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on January 03, 2024, with the firm’s price target at $4-$8.
